Chardan lowered the firm’s price target on Metagenomi (MGX) to $11 from $12. The firm updated its model for Q2 financials and takes a slightly ...

Metagenomi, Inc. (NASDAQ:MGX) just released its latest quarterly results and things are looking bullish. The results overall were credible, with revenues of US$8.5m beating expectations by 10%.

Dr. Reid brings 30 years of experience in building biotech companies based on innovative scientific platforms and shaping ...

In May 2025, the Company reported additional long-term data from its nonhuman primate (“NHP”) study that demonstrated durable and consistent FVIII activity levels through approximately 19 months. Mean ...

Metagenomi (MGX) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to a loss of $0.29 per share a year ago. These figures are ...

Metagenomi raised $175 million in January 2022. According to the IPO paperwork, the biotech had $292.9 million in cash and equivalents as of September 2023, at which point collaboration revenue ...

Metagenomi, a genetic medicines company with a versatile portfolio of wholly owned, next-generation gene editing systems, has been named as one of Fas ...

Moreover, Metagenomi’s diverse gene-editing toolkit is entirely proprietary, granting them the freedom to operate without the need for cross-licensing.

Metagenomi, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before November 25, 2024 to Discuss Your Rights - MGX PR Newswire NEW YORK, Oct. 31, 2024 ...

Metagenomi, Inc. completed its initial public offering on February 13, 2024. The Company sold about 6.25 million shares at $15 per share as part of the IPO. Less than three months later, on May 1 ...

At Metagenomi, we are accelerating innovation in cell and gene therapy with a wave of proprietary CRISPR-based systems to accurately edit DNA where current technologies cannot.

expand Brian Thomas, CEO of Metagenomi Inc. Todd Johnson | San Francisco Business Times By Kevin Truong – Assistant Managing Editor, San Francisco Business Times May 6, 2021 ...